Die Presse, one of Austria’s most respected national newspapers, features our scientific breakthrough in cancer research led by our scientific founder, Prof. Dr. Philipp Jost. Read the full article here.
Cycuria will be attending the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego from December 7- December 10. We look forward to
We’re thrilled to share recent press coverage highlighting Cycuria Therapeutics‘ innovative approach in oncology and our choice to establish roots in Graz’s Medical Science City,
Cycuria will be participating at the upcoming BIO-Europe partnering event in Stockholm, Sweden from 4th-6th Nov. Reach out to schedule one-on-one meeting with our CEO
XIAP discriminates between type I and type II FAS-inducedapoptosis. Nature 2009
At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.